Nasdaq Delisting Notice Hits Lantern Pharma Over $35M Market Value Shortfall
LTRN is trading near its 52-week low of $0.97 (3.1% above the low).
Summary
Lantern Pharma received a Nasdaq delisting notice for failing to maintain the $35 million minimum market value of listed securities. The company has until March 24, 2027, to regain compliance.
Key Events · Legal and Risk Events · LTRN
-
Nasdaq Delisting Notice Received
On September 25, 2026, Nasdaq notified Lantern Pharma that its market value of listed securities had been below the $35 million minimum for 30 consecutive business days, triggering non-compliance with Listing Rule 5550(b)(2).
-
Alternative Listing Standards Also Missed
Nasdaq noted the company also does not meet the requirements under Listing Rules 5550(b)(1) and 5550(b)(3), leaving no alternative compliance path.
-
180-Day Compliance Window
The company has until March 24, 2027, to regain compliance. To do so via the MVLS requirement, its market value of listed securities must close at $35 million or more for a minimum of 10 consecutive business days.
-
Delisting Risk if Not Cured
If compliance is not regained within the 180-day period, Nasdaq would provide notice that the securities are subject to delisting from the Nasdaq Capital Market.
Analysis · LTRN · Life Sciences
A delisting notice from Nasdaq landed on Lantern Pharma on September 25, 2026, after its market value of listed securities stayed below the $35 million minimum for 30 consecutive business days. The company also misses the alternative listing standards under Rules 5550(b)(1) and 5550(b)(3). With a market cap of roughly $12.8 million, regaining compliance would require the market value to more than double and hold above $35 million for 10 consecutive business days by March 24, 2027. This comes just one day after the company closed a $4 million registered direct offering at $1.09 per share, and against a backdrop of a going concern warning disclosed in its Q2 2026 10-Q. A delisting would severely impair liquidity and access to capital for a company already facing cash runway pressure.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.6% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTRN was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $0.97 to $4.70. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.